Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2008-12-05
2010-02-09
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C435S236000
Reexamination Certificate
active
07658932
ABSTRACT:
A method of making an immunogenic composition using inactivated HIV. Inactivation of HIV is through psoralen and ultraviolet radiation. The composition is rendered more effective by the removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune recognition of the composition and to impair Complement Factor H binding. CD55 and CD59 are also removed to prevent the binding of Complement Factor H.A method of making an immunogenic composition using inactivated HIV. Inactivation of HIV is through psoralen and ultraviolet radiation. The composition is rendered more effective by the removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune recognition of the composition and to impair Complement Factor H binding. CD55 and CD59 are also removed to prevent the binding of Complement Factor H.
REFERENCES:
patent: 4169204 (1979-09-01), Hearst
patent: 4960408 (1990-10-01), Klainer
patent: 5106619 (1992-04-01), Wiesehahn
patent: 6107543 (2000-08-01), Sims
patent: 6328968 (2001-12-01), Van Lier et al.
patent: 6383806 (2002-05-01), Rios
patent: 6503753 (2003-01-01), Rios
patent: 6790641 (2004-09-01), Schauber et al.
patent: WO 0220041 (2002-03-01), None
patent: WO 03024435 (2003-03-01), None
Deichmann Marin et al: “Disinfection of Cell-Associated and Extracellular HIV-1 by PUVA Treatment” Journal of Virological Methods, vol. 68, No. 1, 1997, pp. 89-95, CONT.—XP002485905, ISSN: 0166-0934, pp. 94-95; figure 1.
Hart M L et al: “Glycosylation Inhibitors and Neuraminidase Enhance Human Immunodeficiency Virus Type Binding and Neutralization by Mannose-Binding Lextin” CONT.—Journal of General Virology, Society for General Microbiology, Spncers Wood, GB, vol. 84, 2, Feb. 1, 2003, pp. 353-360, XP009019190 ISSN: 0022-1317.
Pinter C et al: “Interference with Complement Regulatory Molecules as a Possible Therapeutic Strategy in HIV Infection” Expert Opinion on Investigational Drugs Feb. 2000 CONT.—vol. 9, No. 2 Feb. 1, 2000, pp. 199-205, XP002484637, pp. 200-201; figures 1, 2.
Saifuddin, M., et al., Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that cont.—protect from complement-mediated destruction J. Gen. Virol. 1997 vol. 78. pp. 1907-1911.
Aiken, C. et al., “Inside-out Regulation of HIV-1 Particle Fusion,” Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA USA Abstract 17 (Feb. 10-14, 2003).
Aroeti, Benjamin, et al., Mutational and Secondary Structural Analysis of the Basolateral Sorting Signal of the Polymeric Immunoglobulin Receptor, J. Cell Biology, vol. 123, No. 5, 1149-1160 (1993).
Ara, Yuki, et al., “Zymozan enhances the immune response to DNA vaccine for human immunodeficiency virus type-I through the activation of complement system” Immunology 103: 98-105 (2001), Japan.
Aslam, Mohammed, et al., “Folded Back Solution Structure of Monomeric Factor H of Human Complement by Synchrotron X-ray and Neutron Scattering, Analytical Ultracentrifugation and Constrained Molecular Modelling,” Molecular Biology, vol. 309, pp. 1117-1138 (2001).
Ault, Bettina, et al., “Human Factor H Deficiency,” Biological Chemistry, vol. 272, #40, pp. 25168-25175 (1997), USA.
Blackmore, T. K., et al., “Identification of a Heparin Binding Domain in the Seventh Short Consensus Repeat of Complement Factor H,” Immunology, vol. 157, Iss 12, pp. 5422-5427 (1996).
Braaten, D., et al., “Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting of human T cells,” the EMBO Journal, vol. 20, No. 6, pp. 1300-1309, 2001.
Brooks, Geo. F., Medical Microbiology Ch. 3 & 7 (23rd Ed. 2004).
Burger, R., et al., “Activation of the alternative pathway of complement: efficient fluid-phase amplification by blockade of the regulatory complement protein B1H through sulfated polyanions,” European J. Immunology, vol. 11, pp. 291-295 (1981).
Doepper, Susi, et al, “Complement Receptors in HIV Infection,” Current Molecular Medicine, vol. 2, Iss 8, pp. 703-711 (2002).
Burger, R., et al., “Dextran Sulphate: a Synthetic Activator of C3 via the Alternative Pathway,” Immunology, vol. 29. pp. 549-554 (1975).
Burger, R., et al., “Insoluble polyanions as activators of both pathways of complement,” Immunology 33:827-837 (1977).
Chan, D. C., et al., “Core Structure of gp41 from the HIV Envelope Glycoprotein” Cell, vol. 89, Issue 2, pp. 263-273 (Apr. 18, 1997).
Chen, Chien-Hung, et al., “Enhancement of DNA Vaccine Potency by Linkage of Antigen Gene to an HSP70 Gene,” Cancer Research 60:1035-1042 (Feb. 15, 2000).
Cheng, Wen-Fang, et al., “Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen,” Journal of Clinical Investigation, vol. 108, No. 5, 669-678 (Sep. 2001).
Hung, Chien-Fu, et al., “Enhancing Major Histocompatibility Complex Class I Antigen Presentation by Targeting Antigen to Centrosomes,” Cancer Research 63: 2393-2398 (May 15, 2003).
Cohen, P.T., The AIDS Knowledge Base, 15-18,21 (3rd ed. 1999).
Cummings, Melissa, et al., New Research Uncovers Potential for More Effective Anti-HIV Therapies: Essential Role of Cyclophilin, Novel Non-Mutable Drug Target Discovered, PR NewsWire 1996.
Dierich, M. P., et al., “HIV and human complement: mechanisms of interaction and biological implication,” Immunology Today, vol. 14, lss 9, pp. 435-440 (1993).
Discipio, R. G., “Ultrastructures and interactions of complement factors H and 1,” .J. Immunology, vol. 149, Iss 8, pp. 2592-2599 (1992).
Fearon, D.T., et al., “Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms,” Proc. Natl. Acad. Sci, vol. 74, No. 4, pp. 1683-1687 (Apr. 1977).
Feifel, Elisabeth, et al., “Polymorphism and deficiency of human factor H-related proteins p39 and p37,” Immunogenetics, vol. 36, pp. 104-109 (1992).
Fishelson, Z., et al., “C3 Convertase of Human Complement: Enhanced Formation and Stability of the Enzyme Generated with Nickel instead of Magnesium,” J. of Immun., vol. 129, No. 6, pp. 2603-2607 (Dec. 1982).
Forrest, Bruce D., et al., “Effect of Parenteral Immunization on the Intestinal Immune Response to Salmonella typhy Ty2la,” Infection and Immunity, vol. 60, No. 2, pp. 465-471 (Feb. 1992).
Franke, E. K., et al., “Chaperoning a pathogen,” Nature, 372 (6504): 319-20 (Nov. 24, 1994).
Franke, E. K., et al., “Specific Incorporation of Cyclophilin A Into HIV-1 Virions,” Nature, 372(6504): 359 (Nov. 24, 1994).
Friese, M. A., “FHL-1/reconectin and factor H: two human complement regulators which are encoded by the same gene are differently expressed and regulated,” Molecular Immunology, vol. 36, pp. 809-818(1999).
Furie, Bruce, “Oral Anticoagulant Therapy,” Hematology Basic Principles & Practice, Ch. 121, pp. 2040-2046 (3rd ed. 2000).
Gardner, William D., “Identification of a major human serum DNA-binding protein as B1H of the alternative pathway of complement activation,” Biochemical and Biophysical Research Communications, vol. 94, pp. 61-67 (1980) .
Gasque, P., “Expression of complement components of the alternative pathway by glioma cell lines,” Immunology, 149:1381-87(1992).
Giannakis, Eleni, et al., “Multiple ligand binding sites on domain seven of human complement factor H,” Int'l. Immunopharmacology, vol. 1, Issue 3, pp. 433-443 (2001).
Goudsmit, J., Immunodominant B-Cell epitopes of the HIV-1 envelope recognized by infected and immunized hosts, AIDS, vol. 2 (Suppl 1): S41-S45 (1988).
Go
Mullen Williams
Parkin Jeffrey S.
LandOfFree
Method of making immunogenic compositions comprising... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of making immunogenic compositions comprising..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of making immunogenic compositions comprising... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4180523